中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 4
Apr.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(4): 872-877

A bibliometric analysis of liver disease research articles published by Chinese mainland authors in Gastroenterology & Hepatology journals indexed in Science Citation Index Expanded

DOI: 10.3969/j.issn.1001-5256.2022.04.024
  • a.

    Division of Clinical Research, The First Hospital of Jilin University, Changchun 130021, China

  • b.

    Department of Hepatology, Center of Infections Diseases and Pathogenic Biology, The First Hospital of Jilin University, Changchun 130021, China

Research funding:

Jilin Province Science and Technology Development Program (20200403098SF);

The Youth Fund of the First Hospital of Jilin University (JDYY11202124)

More Information
  • Corresponding author: JIANG Jing, jiangjing19702000@jlu.edu.cn(ORCID: 0000-0001-9714-9255)
  • Received Date: 2021-09-05
  • Published Date: 2022-04-20
    Abstract
  •   Objective  To investigate the articles on liver diseases published by authors from China (excluding Hong Kong, Macao, and Taiwan regions) in Gastroenterology & Hepatology journals indexed in Science Citation Index Expanded (SCIE) in 2016-2020, to analyze the bibliographic and citation data of these articles, and to understand the contribution and impact of Chinese scholars in the field of liver disease research in recent years.  Methods  The data for bibliometric analysis came from the SCIE database and Journal Citation Reports (JCR). The SCIE database was searched for the journal articles published in JCR Gastroenterology & Hepatology journals in 2016-2020, with a title or abstract containing "Liver", "Hepatocellular", "Hepatitis", "Cirrhosis", or "Hepatic" and a publication type of Article. Clinical guidelines were excluded, and the records with the corresponding author's affiliation containing institutions in China (excluding Hong Kong, Macao, and Taiwan regions) were screened out. R package bibliometrix was used to calculate the frequency of citations of included articles by liver disease studies published by Chinese and global authors in the Gastroenterology & Hepatology journals in 2016-2020, and R package DescTools was used to perform the Cochran-Armitage trend test to observe the change in composition ratio.  Results  In the Q1 Gastroenterology & Hepatology journals in 2016-2020, liver disease studies published by Chinese authors accounted for 9.5%. In recent years, the proportion of liver disease studies published by Chinese authors in Q1 Gastroenterology & Hepatology journals continues to increase from 6.0% to 12.2% (P < 0.001). Among the liver disease studies published by Chinese authors in Q1 Gastroenterology & Hepatology journals, 79.7% were funded by National Natural Science Foundation of China, and there was no significant change in the proportion of studies funded by National Natural Science Foundation of China and published by Chinese authors in each partition of Gastroenterology & Hepatology journals in 2016-2020. The frequency of citations of included articles by liver disease studies published by Chinese and global authors in the Gastroenterology & Hepatology journals showed that liver disease studies published by Chinese authors had a high impact in both domestic and international academic communities.  Conclusion  In recent years, there has been a constant increase in the number of liver disease studies published by Chinese authors in high-impact Gastroenterology & Hepatology journals indexed in SCIE, and most of these studies have been funded by National Natural Science Foundation of China. The liver disease studies published by Chinese authors in Gastroenterology & Hepatology journals have been widely recognized by domestic and international academic communities.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    MAYO CLINIC STAFF. Liver disease[OL]. (2020-2-21)[2021-7-31]. https://www.mayoclinic.org/diseases-conditions/liver-problems/symptoms-causes/syc-20374502.
    [2]
    European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [3]
    ELLEGAARD O, WALLIN JA. The bibliometric analysis of scholarly production: How great is the impact?[J]. Scientometrics, 2015, 105(3): 1809-1831. DOI: 10.1007/s11192-015-1645-z.
    [4]
    YANG HY, WANG D, CHEN C, et al. Global research status of gastroenterology and hepatology: A bibliometrics study[J]. Medicine (Baltimore), 2021, 100(15): e25291. DOI: 10.1097/MD.0000000000025291.
    [5]
    HU SK, HUANG J, HONG WD, et al. The 50 most-cited articles in gastroenterology and hepatology from Mainland China[J]. Pak J Med Sci, 2017, 33(1): 215-220. DOI: 10.12669/pjms.331.12286.
    [6]
    MA HY, AO YK, LIU WB, et al. A bibliometric analysis on cohort study of liver cancer in China[J]. Chin J Epidemiol, 2020, 41(1): 115-119. DOI: 10.3760/cma.j.issn.0254-6450.2020.01.021.

    马宏宇, 敖杨坤, 刘文斌, 等. 中国肝癌相关队列研究的文献计量分析[J]. 中华流行病学杂志, 2020, 41(1): 115-119. DOI: 10.3760/cma.j.issn.0254-6450.2020.01.021.
    [7]
    LI G, LIN J, JIANG C, et al. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: A bibliometric and visual analysis[J]. J Int Med Res, 2020, 48(4): 300060519893234. DOI: 10.1177/0300060519893234.
    [8]
    XU G, JIN B, XIAN X, et al. Evolutions in the management of hepatocellular carcinoma over last 4 decades: An analysis from the 100 most influential articles in the field[J]. Liver Cancer, 2021, 10(2): 137-150. DOI: 10.1159/000513412.
    [9]
    HU AGZ. Public funding and the ascent of Chinese science: Evidence from the National Natural Science Foundation of China[J]. Research Policy, 2020, 49(5): 13. DOI: 10.1016/j.respol.2020.103983.
    [10]
    LIU Y, GAO Z, WANG H, et al. Analysis of projects funded by the National Natural Science Foundation of China during the years of 2014-2018[J]. Ann Transl Med, 2019, 7(12): 267. DOI: 10.21037/atm.2019.05.63.
    [11]
    R CORE TEAM. R: A language and environment for statistical computing[OL]. https://www.R-project.org/.
    [12]
    ARIA M, CUCCURULLO C. bibliometrix: An R-tool for comprehensive science mapping analysis[J]. J Informetr, 2017, 11(4): 959-975. DOI: 10.1016/j.joi.2017.08.007.
    [13]
    SIGNORELL A. DescTools: Tools for descriptive statistics[OL]. https://cran.r-project.org/package=DescTools.
    [14]
    NESHAT SY, QUIROZ VM, WANG Y, et al. Liver disease: Induction, progression, immunological mechanisms, and therapeutic interventions[J]. Int J Mol Sci, 2021, 22(13): 6777. DOI: 10.3390/ijms22136777.
    [15]
    IOANNOU GN, GREEN PK, BERRY K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma[J]. J Hepatol, 2018, 68(1): 25-32. DOI: 10.1016/j.jhep.2017.08.030.
    [16]
    EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
    [17]
    BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66. DOI: 10.1016/S0140-6736(16)32453-9.
    [18]
    LOOMBA R, ADAMS LA. Advances in non-invasive assessment of hepatic fibrosis[J]. Gut, 2020, 69(7): 1343-1352. DOI: 10.1136/gutjnl-2018-317593.
    [19]
    RUDIGER MS, ANTONS D, SALGE TO. The explanatory power of citations: A new approach to unpacking impact in science[J]. Scientometrics, 2021, 126: 9779-9809. DOI: 10.1007/s11192-021-04103-w.
    [20]
    ZHU HR. Home country bias in academic publishing: A case study of the New England Journal of Medicine[J]. Learned Publishing, 2021, 34(4): 578-584. DOI: 10.1002/leap.1404.
    [21]
    WANG J, SHEN T, HUANG X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4): 700-710. DOI: 10.1016/j.jhep.2016.05.029.
    [22]
    XU X, LU D, LING Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6): 1035-1041. DOI: 10.1136/gutjnl-2014-308513.
    [23]
    SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450. DOI: 10.1002/hep.29009.
    [24]
    LV Y, QI X, HE C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: A randomised controlled trial[J]. Gut, 2018, 67(12): 2156-2168. DOI: 10.1136/gutjnl-2017-314634.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (649) PDF downloads(71) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return